Table 2.
Adverse event of different anlotinib dose groups
| Adverse events (n = 21) | Any grade (n, %) | Grade 1 (n, %) | Grade 2 (n, %) | Grade 3 or 4 (n, %) |
|---|---|---|---|---|
| Hand-foot syndrome | 2 (5.00) | 0 | 2 (5.00) | 0 |
| Hypertension | 2 (5.00) | 1 (2.50) | 0 | 1 (2.50) |
| Hemoptysis | 2 (5.00) | 0 | 2 (5.00) | 0 |
| Thyroid dysfunction | 2 (5.00) | 0 | 2 (5.00) | 0 |
| Diarrhea | 1 (2.50) | 1 (2.50) | 0 | 0 |
| Immune hepatitis | 1 (2.50) | 1 (2.50) | 0 | 0 |
| Gastrointestinal reactions | 4 (10.00) | 2 (5.00) | 2 (5.00) | 0 |
| Abnormal liver function | 2 (5.00) | 2 (5.00) | 0 | 0 |
| Weakness | 2 (5.00) | 0 | 2 (5.00) | 0 |
| Oral mucosa syndrome | 1 (2.50) | 1 (2.50) | 0 | 0 |
| Hyperglycemia | 1 (2.50) | 1 (2.50) | 0 | 0 |
| Immune myocarditis | 1 (2.50) | 0 | 1 (2.50) | 0 |